Leggett P L, Doyle D, Smith W B, Culpepper W, Cooper S, Ochsner J L
J Thorac Cardiovasc Surg. 1984 Apr;87(4):556-60.
This paper describes a successful cardiac operation in a young boy with hemophilia, congenital heart disease, severe factor VIII deficiency, and an acquired high titer antibody to factor VIII. To our knowledge, there have been no published cases of elective cardiac operations in a person with severe hemophilia and an accompanying complex problem. Utilizing the team approach, we administered a megadose bolus of factor VIII concentrate preoperatively (eight times the calculated dose), followed by a continuous intravenous infusion at 500 units/hr throughout the procedure and at a reduced dose for the first 5 postoperative days. With the anamnestic rise in factor VIII antibody on day 5, activated prothrombin complex concentrates were substituted for factor VIII and provided continued adequate hemostasis during the remaining 9 postoperative days. The rapid infusion of large quantities of factor VIII was effective in neutralizing the low titer inhibitor and providing normal hemostasis during the procedure. In addition, activated prothrombin complex concentrates were substituted for factor VIII coagulant without recurrent bleeding or thromboembolic phenomena.
本文描述了一名患有血友病、先天性心脏病、严重凝血因子 VIII 缺乏症以及获得性高滴度凝血因子 VIII 抗体的小男孩成功接受心脏手术的案例。据我们所知,此前尚无关于严重血友病患者伴有复杂问题时进行择期心脏手术的病例报道。我们采用团队协作的方法,术前给予大剂量凝血因子 VIII 浓缩剂推注(计算剂量的八倍),随后在整个手术过程中以每小时 500 单位的速度持续静脉输注,并在术后头 5 天给予减量输注。术后第 5 天,随着凝血因子 VIII 抗体的回忆性升高,用活化凝血酶原复合物浓缩剂替代凝血因子 VIII,并在术后剩余的 9 天内持续提供足够的止血效果。大量快速输注凝血因子 VIII 有效地中和了低滴度抑制剂,并在手术过程中实现了正常止血。此外,用活化凝血酶原复合物浓缩剂替代凝血因子 VIII 凝血剂后,未出现复发性出血或血栓栓塞现象。